MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value of Financial Liabilities (Tables)

Fair Value of Financial Liabilities (Tables)

6 Months Ended

Jun. 30, 2024

Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities

Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:


	Fair value at December 31, 2023
	Total		Level 1		Level 2		Level 3
Liabilities:
Warrant liability		2,152,188		—		—		2,152,188
Total liabilities	$	2,152,188	$	—	$	—	$	2,152,188


	Fair value at June 30, 2024
	Total		Level 1		Level 2		Level 3
Liabilities:
Warrant liability		5,346,638		—		—		5,346,638
Total liabilities	$	5,346,638	$	—	$	—	$	5,346,638

Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities

The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):


	Three Months Ended June 30,						Six Months Ended June 30,
Warrant liabilities:	2024			2023			2024			2023
Balance, beginning of period	$	9,573,197		$	224,399		$	2,152,188		$	245,341
Issuance of warrants		677,919			—			3,917,630			—
Exercises of warrants		(3,191,675	)		—			(3,191,675	)		—
Amendments of warrants		(6,870,296	)		—			(6,870,296	)		—
Loss (Gain) on fair value of warrant liability		5,157,493			(102,799	)		9,338,791			(123,741	)
Balance, end of period		5,346,638			121,600			5,346,638			121,600